<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Eosinophilic esophagitis (EoE): Genetics and immunopathogenesis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Eosinophilic esophagitis (EoE): Genetics and immunopathogenesis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Eosinophilic esophagitis (EoE): Genetics and immunopathogenesis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc E Rothenberg, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Scott H Sicherer, MD, FAAAAI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H20860156">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eosinophilic esophagitis (EoE) is a chronic, immune/antigen-mediated esophageal disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation [
         <a href="#rid1">
          1
         </a>
         ]. The pathogenesis of EoE is the result of an interplay among genetic, environmental, and host immune system factors.
        </p>
        <p>
         This topic reviews the genetics and immunopathogenesis underlying EoE. The clinical features, diagnosis, and management of EoE are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">
          "Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16604.html" rel="external">
          "Allergy testing in eosinophilic esophagitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2247.html" rel="external">
          "Treatment of eosinophilic esophagitis (EoE)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16606.html" rel="external">
          "Dietary management of eosinophilic esophagitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17470358">
         <span class="h1">
          OVERVIEW OF PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of EoE is incompletely understood but involves genetic, environmental, and host immune system factors. Molecular analysis has elucidated that EoE is caused by a primary defect in esophageal epithelial function rather than an eosinophil defect. This is best illustrated by the finding that genetic susceptibility is mediated by genes expressed by the esophageal epithelia rather than eosinophils. The esophagus of EoE patients has an impairment of epithelial cell differentiation and barrier function.
        </p>
        <p>
         The esophagus is normally devoid of eosinophils, although they are permanent residents in the rest of the gastrointestinal tract beginning during early embryonic development. Thus, the finding of esophageal eosinophils denotes pathology, typically EoE or gastroesophageal reflux disease (GERD) [
         <a href="#rid2">
          2,3
         </a>
         ]. The diagnosis of EoE originally required the presence of esophageal eosinophilia that was resistant to proton pump inhibitor (PPI) therapy. It is now appreciated that a substantial number of patients with esophageal eosinophilia can respond to PPI therapy, an entity that was referred to as PPI-responsive esophageal eosinophilia (PPI-REE) [
         <a href="#rid4">
          4
         </a>
         ]. It is increasingly appreciated that PPI-REE may be nearly indistinguishable from EoE based upon clinical, endoscopic, histologic, and molecular features [
         <a href="#rid4">
          4
         </a>
         ]. As such, the PPI requirement to diagnosis EoE is no longer a requirement, and PPIs are now considered a therapy for EoE. As such, the diagnosis of EoE is solely based upon the requisite level of eosinophils (at least 15 eosinophils per high-powered field) in patients with clinical manifestations [
         <a href="#rid5">
          5
         </a>
         ]. Diagnosing EoE and differentiating it from GERD are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">
          "Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)", section on 'Distinction from GERD'
         </a>
         .)
        </p>
        <p>
         Antigenic proteins, typically derived from food and less commonly from inhaled proteins, trigger an adaptive T helper type 2 (Th2) cell-mediated response that produces cytokines, such as interleukin (IL) 5 and IL-13 [
         <a href="#rid6">
          6
         </a>
         ]. IL-13 subsequently triggers resident cells, such as esophageal epithelial cells, to produce a large set of proteins. The most strongly induced gene in this process is eotaxin 3, which in turn recruits eosinophils from the peripheral blood into the tissue [
         <a href="#rid7">
          7
         </a>
         ]. Antigen-driven Th2 cells also produce IL-5 and IL-13. IL-5 is a chief eosinophil growth and activation factor that primes eosinophils to have enhanced responsiveness to eotaxin 3 and prolongs their cellular survival. IL-13 induces other key mediators of EoE including eotaxin 3 and calpain 14 (
         <em>
          CAPN14
         </em>
         ; the gene product of the primary EoE susceptibility locus) [
         <a href="#rid8">
          8
         </a>
         ]. These type 2 cytokines are largely produced by activated effector memory pathogenic CD4
         <sup>
          +
         </sup>
         T cells that accumulate in the esophagus [
         <a href="#rid9">
          9
         </a>
         ]. IL-13 also decreases the expression of genes that encode proteins involved in barrier function such as filaggrin and components of esophageal desmosomes, such as desmoglein 1 [
         <a href="#rid10">
          10
         </a>
         ]. Rare genetic loss-of-function variants in other desmosome genes, including those encoding periplakin and desmoplakin, are also associated with EoE [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20860162">
         <span class="h1">
          ROLE OF THE IMMUNE SYSTEM AND ENVIRONMENTAL FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Host immune system mechanisms in EoE appear to fall somewhere in between pure immunoglobulin E (IgE) mediated and delayed T helper type 2 (Th2) responses [
         <a href="#rid3">
          3,12-14
         </a>
         ]. Eosinophils, T cells, and mast cells are elevated in esophageal mucosal biopsies [
         <a href="#rid15">
          15
         </a>
         ], and mast cell degranulation and eosinophil cytolysis and degranulation are common findings in tissue specimens from patients with eosinophilic gastrointestinal disorders (EGIDs) [
         <a href="#rid16">
          16-18
         </a>
         ]. Mast cell levels are more closely linked with clinical symptoms than eosinophil levels [
         <a href="#rid19">
          19
         </a>
         ]. Studies have identified contributory roles for allergens, cytokines, micro-ribonucleic acid (microRNA or miRNA), chemokines, and polarization of Th2 immunity in the disease pathophysiology. In addition, EoE is uniquely characterized by high levels of systemic and esophageal immunoglobulin G4 (IgG4), which include food-specific responses [
         <a href="#rid20">
          20-22
         </a>
         ]. The high levels of IgG4 may play a role in blocking IgE responses and may explain the dissociation between the absence of positive skin tests and effective elimination diets.
        </p>
        <p class="headingAnchor" id="H17470568">
         <span class="h2">
          Allergens
         </span>
         <span class="headingEndMark">
          —
         </span>
         The association of EoE with allergies suggests that eosinophil recruitment to the esophagus may be an immune response to environmental antigens in genetically predisposed individuals. Several lines of evidence support an allergic etiology. The role of allergies in EoE is briefly reviewed here and is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16604.html" rel="external">
          "Allergy testing in eosinophilic esophagitis", section on 'Evidence for role of allergies in EoE'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16606.html" rel="external">
          "Dietary management of eosinophilic esophagitis"
         </a>
         .)
        </p>
        <p>
         Approximately 75 percent of patients with EoE or other EGIDs are atopic [
         <a href="#rid23">
          23-32
         </a>
         ]. The majority of patients have evidence of food allergen and aeroallergen sensitization, as defined by skin prick and/or allergen-specific IgE tests, although only a minority has a history of food anaphylaxis (an IgE-mediated reaction) [
         <a href="#rid2">
          2
         </a>
         ]. EoE can typically be reversed by institution of an allergen-free diet [
         <a href="#rid23">
          23,24,33,34
         </a>
         ], and relapse is common upon food reintroduction [
         <a href="#rid1">
          1
         </a>
         ]. In addition, priming with epicutaneous exposure to antigens can result in esophageal eosinophil recruitment in a mouse model [
         <a href="#rid35">
          35
         </a>
         ]. Patients with EoE also frequently report seasonal variations in their symptoms, with fewer cases being diagnosed in the winter months (when outdoor aeroallergens are relatively low) [
         <a href="#rid36">
          36-38
         </a>
         ]. In addition, increased eosinophil accumulation is seen in the esophagus of patients with EoE and seasonal allergic rhinitis with hypersensitivity to grass pollen [
         <a href="#rid39">
          39
         </a>
         ]. EoE has also been reported in a few patients treated with sublingual pollen immunotherapy [
         <a href="#rid40">
          40,41
         </a>
         ] and can be triggered by oral immunotherapy [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17470669">
         <span class="h2">
          Eosinophils and chemokines
         </span>
         <span class="headingEndMark">
          —
         </span>
         EoE typically occurs in the absence of substantial peripheral blood eosinophilia, indicating the potential significance of esophageal-specific mechanisms for regulating eosinophil levels. When blood eosinophilia occurs in EoE, it is typically mild in magnitude (&lt;500 cells/microL of blood). Eotaxin plays a central role in antigen-mediated eosinophil recruitment [
         <a href="#rid6">
          6,7,43,44
         </a>
         ], and the importance of a local eotaxin pathway in this process has been demonstrated in several studies [
         <a href="#rid43">
          43-48
         </a>
         ]. Collectively, these results strongly implicate eotaxin 3 in the pathoetiology of EoE and offer a molecular connection between Th2 inflammation and the development of EoE.
        </p>
        <p>
         In murine models of EoE, eosinophil recruitment is attenuated in the absence of eotaxin [
         <a href="#rid47">
          47
         </a>
         ], and mice with a genetic ablation of the eotaxin receptor (C-C motif chemokine receptor 3 [CCR3]) are protected from the development of experimental EoE [
         <a href="#rid45">
          45
         </a>
         ]. The later study also reported on a genome-wide microarray expression profile analysis of esophageal tissue that was used to compare gene transcript expression in the esophageal tissue of patients with EoE or chronic esophagitis (typical of gastroesophageal reflux disease [GERD]) and normal individuals. Eotaxin 3 (also called chemokine [C-C motif] ligand 26,
         <em>
          CCL26
         </em>
         ) was the most overexpressed gene in patients with EoE.
        </p>
        <p>
         Levels of eotaxin 3 correlated with disease severity in a study in which overexpression of eotaxin 3 alone had a predictive value of 89 percent in diagnosing EoE from a single esophageal biopsy [
         <a href="#rid46">
          46
         </a>
         ]. Another study demonstrated that treatment of EoE with topical glucocorticoids downregulated esophageal eotaxin 3 levels (as well as other cytokines implicated in EoE) [
         <a href="#rid48">
          48
         </a>
         ]. A number of studies in experimental systems in rodents have shown that eosinophils have an effector role in mediating the pathologic features of EoE [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17470704">
         <span class="h2">
          Th2 immunity and cytokines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adaptive T cell immunity, driven by T helper type 2 (Th2) cells and involving interleukin (IL) 13, IL-5, and IL-20 family member expression, appears to play a major role in the pathogenesis of EoE [
         <a href="#rid9">
          9,15,50-54
         </a>
         ].
        </p>
        <p>
         Studies of cytokines in EoE have shown the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IL-5 is expressed by Th2 cells and eosinophils. It is a key mediator in eosinophil activation and appears to mediate eosinophil-induced esophageal remodeling and collagen deposition [
         <a href="#rid49">
          49
         </a>
         ]. IL-5 expression is increased in tissue samples from children with EoE [
         <a href="#rid55">
          55
         </a>
         ]. In a murine model of EoE, eosinophil recruitment was ablated in the absence of IL-5 [
         <a href="#rid47">
          47
         </a>
         ]. Overexpression of IL-5 in mice leads to increased esophageal eosinophils, and development of EoE is blocked in IL-5-deficient mice [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IL-13 is secreted by Th2 cells in particular. One of its effects is to increase eotaxin 3 expression. Elevated levels of IL-13 messenger RNA (mRNA) are seen in esophageal biopsy specimens from patients with EoE [
         <a href="#rid57">
          57
         </a>
         ]. These findings are ablated with glucocorticoid treatment. In addition, IL-13 stimulation induces an EoE-specific esophageal transcriptome, as well as the gene product from the main EoE susceptibility locus,
         <em>
          CAPN14
         </em>
         [
         <a href="#rid58">
          58,59
         </a>
         ]. Repeated delivery of specific allergens or IL-13 to the lung of mice, as well transgenic overexpression of IL-13 in the lung of mice, induces experimental EoE [
         <a href="#rid52">
          52,60,61
         </a>
         ], suggesting that esophageal eosinophilic inflammation is mechanistically linked with pulmonary inflammation. Blockade of IL-13 in vivo with human anti-IL-13 antibodies attenuates esophageal eosinophilia and clinical features and improves endoscopic and molecular markers of EoE [
         <a href="#rid62">
          62,63
         </a>
         ]. The key role of IL-13 and the related cytokine IL-4 is best exemplified by the ability of
         <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">
          dupilumab
         </a>
         to improve symptomatic, endoscopic, histologic, and molecular aspects of EoE [
         <a href="#rid63">
          63
         </a>
         ], resulting in its US Food and Drug Administration (FDA) approval as the first drug for EoE. (See
         <a class="local">
          'Mast cells'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2247.html" rel="external">
          "Treatment of eosinophilic esophagitis (EoE)", section on 'Dupilumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thymic stromal lymphopoietin (TSLP) promotes Th2 responses, and elevated levels of TSLP are found in the esophagus of patients with EoE [
         <a href="#rid64">
          64
         </a>
         ]. TSLP and its receptor, in concert with transforming growth factor beta 1 (TGF-beta-1), affect tolerance mechanisms in dendritic cells in vitro [
         <a href="#rid65">
          65
         </a>
         ]. This suggests mechanistically that food tolerance mechanisms are disrupted in patients with EoE. A nonsynonymous polymorphism in the gene for the TSLP receptor was associated with EoE in male patients only [
         <a href="#rid66">
          66
         </a>
         ]. TSLP is overproduced in the absence of the anti-protease serine peptidase inhibitor, kazal type 7 (SPINK7), which is deficient in the esophagus of patients with EoE [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="local">
          'Genetic defects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased expression of fibroblast growth factor 9 (
         <em>
          FGF9
         </em>
         ) and other profibrogenic cytokine genes, such as IL-5 in the subepithelial layer of the esophagus, is seen in patients with EoE, suggesting that these cytokines may have a role in the fibrogenic response [
         <a href="#rid68">
          68,69
         </a>
         ]. Prolonged treatment with swallowed glucocorticoids is associated with a downregulation of profibrogenic cytokine gene expression [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IL-20 subfamily members, IL-19, IL-20, and IL-24, are increased in the esophagus of EoE patients. Their overexpression induces epithelial barrier defects. Experimental knockout of the IL-20 receptor attenuated experimental EoE associated with esophageal eosinophilia, loss of filaggrin, and type 2 cytokine production [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H55380336">
         <span class="h2">
          Mast cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         The exact role of mast cells in EoE is unclear. Increased numbers of mast cells are seen in esophageal tissue samples from patients with EoE, and degranulation is common [
         <a href="#rid71">
          71
         </a>
         ]. Results from a murine model of EoE suggest that mast cells may have an important role in esophageal remodeling in EoE by promoting muscle cell hyperplasia and hypertrophy [
         <a href="#rid72">
          72
         </a>
         ]. Elevated TGF-beta, produced by eosinophils and mast cells, contributes to esophageal tissue remodeling and smooth muscle dysfunction in patients with EoE, similar to that seen in the airways of patients with asthma [
         <a href="#rid73">
          73
         </a>
         ], further supporting the link between esophageal and pulmonary inflammation. However,
         <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">
          cromolyn
         </a>
         sodium, a mast cell stabilizer, has shown little benefit in the treatment of EoE [
         <a href="#rid74">
          74
         </a>
         ]. (See
         <a class="local">
          'Th2 immunity and cytokines'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H97327672">
         <span class="h2">
          MicroRNA
         </span>
         <span class="headingEndMark">
          —
         </span>
         MicroRNAs (miRNAs) act as regulators of mRNA expression and translation. In one study, esophageal microRNA expression correlated with eosinophil levels [
         <a href="#rid75">
          75
         </a>
         ]. miR-21 and miR-223 showed the greatest upregulation in patients with EoE compared with normal controls. These two microRNAs may play a role in regulation of eosinophilia and polarization of adaptive immunity. miR-375 was the most downregulated. Levels of these microRNAs mostly reverted to normal with glucocorticoid treatment. Patients in remission showed increased expression of miR-675. In the plasma, the most differentially expressed microRNAs were miR-146a, miR-146b, and miR-223.
        </p>
        <p class="headingAnchor" id="H20860190">
         <span class="h1">
          GENETICS AND FAMILY HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A genetic predisposition to EoE is supported by evidence of familial clustering [
         <a href="#rid76">
          76
         </a>
         ] and twin studies, which have revealed a 58 percent concordance in monozygotic twins and a 36 percent concordance in dizygotic twins compared with regular fraternal siblings [
         <a href="#rid77">
          77
         </a>
         ]. The risk of EoE for other siblings is 2 to 3 percent. Collectively, twin studies have indicated a strong heritability of EoE, largely accounted for by shared environment in early life.
        </p>
        <p>
         Early-life exposures modify the risk of EoE, with maternal fever, pre- and postnatal antibiotics, proton pump inhibitor (PPI) therapy, and neonatal intensive care unit admission associated with increased risk of EoE and pet exposure in the first year of life associated with a decreased risk of EoE [
         <a href="#rid78">
          78
         </a>
         ]. Indeed, the esophagus harbors a unique microbiome, and dysbiosis increases IgE and EoE susceptibility [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         In addition, several genetic variants that may predispose to EoE have been identified, especially at 5q22 (
         <em>
          TSLP
         </em>
         gene) and 2p23 (
         <em>
          CAPN14
         </em>
         gene) [
         <a href="#rid80">
          80
         </a>
         ]. The identified genetic markers for EoE are primarily common genetic variants, although one appears to be specific for EoE.
         <em>
          CAPN14
         </em>
         is induced by interleukin (IL) 13 in esophageal epithelial cells and is involved in regulating barrier function, an impaired process germane to the development of EoE [
         <a href="#rid58">
          58,59,81
         </a>
         ]. Very early onset of EoE (first 18 months of life) is particularly enriched in genetic variants in the
         <em>
          CAPN14
         </em>
         gene, as well as associated with cesarean birth compared with late-onset EoE [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H55380564">
         <span class="h2">
          Family history
         </span>
         <span class="headingEndMark">
          —
         </span>
         Over 30 families with multiple affected individuals were reported by 2008 [
         <a href="#rid83">
          83
         </a>
         ]. In a study of 103 children with EoE, a positive family history was observed in 7 percent [
         <a href="#rid76">
          76
         </a>
         ]. This included three sibling pairs and the mother of one of the pairs of siblings. A report from an eosinophilic gastrointestinal disorder (EGID) registry database showed that 16 percent of patients had an immediate family member with a similar disorder [
         <a href="#rid84">
          84
         </a>
         ]. Almost 10 percent of patients with EoE and evidence of esophageal strictures have parents diagnosed with EoE [
         <a href="#rid3">
          3
         </a>
         ]. There is also a large sibling risk ratio, estimated at approximately 50-fold compared with the general population [
         <a href="#rid3">
          3
         </a>
         ]. This translates into 3 percent of patients with EoE having siblings who develop EoE. A number of rare genetic variants are responsible for familial presentations of EoE including predicted damaging variants in the mitochondrial genes encoding oxidoreductases dehydrogenase E1 and transketolase domain containing 1 (DHTKD1) and oxoglutarate dehydrogenase L (OGDHL) [
         <a href="#rid85">
          85,86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H55380570">
         <span class="h2">
          Genetic defects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The earliest work demonstrating that genetic factors have a role revealed dysregulated expression of approximately 1 percent of the entire human genome, constituting an EoE genetic signature [
         <a href="#rid45">
          45
         </a>
         ]. Additional dysregulated transcripts, including several long-noncoding RNAs (lcnRNAs) that act as transcriptional regulators, were identified when RNA sequencing on esophageal biopsies was performed [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
         An EoE susceptibility locus was also identified at 5q22, involving the gene encoding TSLP [
         <a href="#rid64">
          64
         </a>
         ]. The genes for TSLP and its receptor are both associated with EoE [
         <a href="#rid65">
          65
         </a>
         ]. In addition, genetic susceptibility has been found at 5p23, encoding for the
         <em>
          CAPN14
         </em>
         gene [
         <a href="#rid58">
          58
         </a>
         ]. Calpain 14 is an esophageal-specific enzyme that regulates IL-13 responses in esophageal epithelial cells and probably explains, at least in part, the tissue-specific nature of the disease [
         <a href="#rid59">
          59
         </a>
         ]. Multiple genetic events collectively contribute to EoE, including an interplay of atopy genes with EoE-specific elements [
         <a href="#rid88">
          88
         </a>
         ]. Meta-analyses of genome-wide association studies have identified at least six other susceptibility loci including EMSY transcriptional repressor, BRCA2 interacting (
         <em>
          EMSY
         </em>
         )/leucine rich repeat containing 32 (
         <em>
          LRRC32
         </em>
         ; 11q13) and BTB domain and CNC homolog 2 (
         <em>
          BACH2
         </em>
         ; 6q15) [
         <a href="#rid89">
          89,90
         </a>
         ].
        </p>
        <p>
         EoE involves loss of esophageal barrier function, mediated by depressed expression of desmoglein 1 and SPINK7 [
         <a href="#rid18">
          18,67
         </a>
         ], associated with a loss of epithelial cell differentiation [
         <a href="#rid91">
          91
         </a>
         ]. In addition, genetic variants in the filaggrin gene are linked with EoE, highlighting the potential key role of alterations in barrier function in EoE. Finally, genetic variants in transforming growth factor (TGF) receptors and/or genes associated with inherited connective tissue disorders involving hypermobility syndrome are associated with EoE [
         <a href="#rid65">
          65
         </a>
         ]. These genetic findings have provided insight into molecular etiology and disease susceptibility, but they have not elucidated why patients develop the tissue-specific response characteristic of EoE, since genes such as
         <em>
          TSLP
         </em>
         have been linked with other atopic disorders.
        </p>
        <p>
         Relatively large genome-wide association studies and meta-analyses have determined that a major susceptibility linkage exists at 2p23 [
         <a href="#rid58">
          58
         </a>
         ]. This region of the chromosome contains the
         <em>
          CAPN14
         </em>
         gene, which encodes for calpain 14. This protein is specifically expressed in the esophagus, is markedly upregulated in patients with EoE compared with controls in a manner dependent upon the
         <em>
          CAPN14
         </em>
         genotype, and is dramatically induced by IL-13 in esophageal epithelial cells by an epigenetic mechanism. (See
         <a class="local">
          'Th2 immunity and cytokines'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H707266784">
         <span class="h2">
          EoE molecular transcriptome
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 96-gene EoE diagnostic panel (EDP) has been developed based upon analysis of esophageal biopsies and is available commercially. The EDP provides deep information concerning the contribution of individual genes to the pathogenesis of EoE, especially on a patient-to-patient basis [
         <a href="#rid92">
          92
         </a>
         ]. This diagnostic panel, which differentiates EoE from control individuals, including those with gastroesophageal reflux disease (GERD), can also differentiate patients with active and inactive disease and identify glucocorticoid exposure, providing substantial clinical value. Combining analysis of EDP with endoscopic, histologic, and clinical features has led to the identification of three different EoE endotypes that have different disease features and possibly unique course and response to therapy [
         <a href="#rid93">
          93
         </a>
         ]. Molecular profiling has also revealed variable disease groups based upon differential expression of type 2 cytokine-related genes [
         <a href="#rid94">
          94
         </a>
         ]. Genetic testing for the EoE molecular transcriptome may be useful in both diagnosis and management of EoE. (See
         <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">
          "Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)", section on 'Subtypes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">
          "Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)", section on 'Laboratory tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H97328026">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Eosinophilic esophagitis (EoE) is a chronic, immune/antigen-mediated esophageal disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The pathogenesis of EoE is incompletely understood but involves an interplay between genetic, environmental, and host immune system factors. Molecular analysis has elucidated that EoE is caused by a primary defect in esophageal epithelial function rather than an eosinophil defect. The esophagus of EoE patients has an impairment of epithelial cell differentiation and barrier function. (See
         <a class="local">
          'Overview of pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of host immune system
         </strong>
         – Host immune system mechanisms in EoE appear to fall somewhere in between pure immunoglobulin E (IgE) mediated and delayed T helper type 2 (Th2) responses. Studies have identified contributory roles for allergens, cytokines, microRNAs (miRNAs), chemokines, and polarization of Th2 immunity in the disease pathophysiology. The role of type 2 immunity is underscored by the US Food and Drug Administration (FDA) approval of
         <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">
          dupilumab
         </a>
         (anti-type 2 biological agent) for the treatment of EoE. (See
         <a class="local">
          'Role of the immune system and environmental factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – A genetic predisposition to EoE is supported by evidence of familial clustering and twin studies. In addition, several genetic defects that may predispose to EoE have been identified, especially at 2p23, encoding for the esophagus specific gene product, calpain 14. Genetic testing for the EoE molecular transcriptome is available and may be useful in diagnosis, disease subgroup identification (endotyping), and management of EoE. (See
         <a class="local">
          'Genetics and family history'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox VL, Nurko S, Furuta GT. Eosinophilic esophagitis: it's not just kid's stuff. Gastrointest Endosc 2002; 56:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 2004; 113:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut 2016; 65:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology 2018; 155:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogan SP, Mishra A, Brandt EB, et al. A critical role for eotaxin in experimental oral antigen-induced eosinophilic gastrointestinal allergy. Proc Natl Acad Sci U S A 2000; 97:6681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishra A, Hogan SP, Lee JJ, et al. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 1999; 103:1719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litosh VA, Rochman M, Rymer JK, et al. Calpain-14 and its association with eosinophilic esophagitis. J Allergy Clin Immunol 2017; 139:1762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen T, Aronow BJ, Rochman Y, et al. Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis. J Clin Invest 2019; 129:2014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherrill JD, Kc K, Wu D, et al. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol 2014; 7:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoda T, Kaufman KM, Wen T, et al. Desmoplakin and periplakin genetically and functionally contribute to eosinophilic esophagitis. Nat Commun 2021; 12:6795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampson HA. Food allergy. Part 2: diagnosis and management. J Allergy Clin Immunol 1999; 103:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampson HA. Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol 1999; 103:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bischoff S, Crowe SE. Gastrointestinal food allergy: new insights into pathophysiology and clinical perspectives. Gastroenterology 2005; 128:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 2001; 108:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oyaizu N, Uemura Y, Izumi H, et al. Eosinophilic gastroenteritis. Immunohistochemical evidence for IgE mast cell-mediated allergy. Acta Pathol Jpn 1985; 35:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saffari H, Hoffman LH, Peterson KA, et al. Electron microscopy elucidates eosinophil degranulation patterns in patients with eosinophilic esophagitis. J Allergy Clin Immunol 2014; 133:1728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherrill JD, Rothenberg ME. Genetic and epigenetic underpinnings of eosinophilic esophagitis. Gastroenterol Clin North Am 2014; 43:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang S, Shoda T, Aceves SS, et al. Mast cell-pain connection in eosinophilic esophagitis. Allergy 2022; 77:1895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright BL, Kulis M, Guo R, et al. Food-specific IgG4 is associated with eosinophilic esophagitis. J Allergy Clin Immunol 2016; 138:1190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clayton F, Fang JC, Gleich GJ, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology 2014; 147:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zukerberg L, Mahadevan K, Selig M, Deshpande V. Oesophageal intrasquamous IgG4 deposits: an adjunctive marker to distinguish eosinophilic oesophagitis from reflux oesophagitis. Histopathology 2016; 68:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spergel JM, Beausoleil JL, Mascarenhas M, Liacouras CA. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol 2002; 109:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh SV, Antonioli DA, Goldman H, et al. Allergic esophagitis in children: a clinicopathological entity. Am J Surg Pathol 1999; 23:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caldwell JH, Sharma HM, Hurtubise PE, Colwell DL. Eosinophilic gastroenteritis in extreme allergy. Immunopathological comparison with nonallergic gastrointestinal disease. Gastroenterology 1979; 77:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caldwell JH, Tennenbaum JI, Bronstein HA. Serum IgE in eosinophilic gastroenteritis. Response to intestinal challenge in two cases. N Engl J Med 1975; 292:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cello JP. Eosinophilic gastroenteritis--a complex disease entity. Am J Med 1979; 67:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scudamore HH, Phillips SF, Swedlund HA, Gleich GJ. Food allergy manifested by eosinophilia, elevated immunoglobulin E level, and protein-losing enteropathy: the syndrome of allergic gastroenteropathy. J Allergy Clin Immunol 1982; 70:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuta GT, Ackerman SJ, Wershil BK. The role of the eosinophil in gastrointestinal diseases. Curr Opin Gastroenterol 1995; 11:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iacono G, Carroccio A, Cavataio F, et al. Gastroesophageal reflux and cow's milk allergy in infants: a prospective study. J Allergy Clin Immunol 1996; 97:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampson HA. Food allergy. JAMA 1997; 278:1888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodruff SA, Masterson JC, Fillon S, et al. Role of eosinophils in inflammatory bowel and gastrointestinal diseases. J Pediatr Gastroenterol Nutr 2011; 52:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 1995; 109:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2012; 129:1570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akei HS, Mishra A, Blanchard C, Rothenberg ME. Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice. Gastroenterology 2005; 129:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad GA, Alexander JA, Schleck CD, et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2009; 7:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang FY, Gupta SK, Fitzgerald JF. Is there a seasonal variation in the incidence or intensity of allergic eosinophilic esophagitis in newly diagnosed children? J Clin Gastroenterol 2007; 41:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almansa C, Krishna M, Buchner AM, et al. Seasonal distribution in newly diagnosed cases of eosinophilic esophagitis in adults. Am J Gastroenterol 2009; 104:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onbasi K, Sin AZ, Doganavsargil B, et al. Eosinophil infiltration of the oesophageal mucosa in patients with pollen allergy during the season. Clin Exp Allergy 2005; 35:1423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antico A, Fante R. Esophageal hypereosinophilia induced by grass sublingual immunotherapy. J Allergy Clin Immunol 2014; 133:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miehlke S, Alpan O, Schröder S, Straumann A. Induction of eosinophilic esophagitis by sublingual pollen immunotherapy. Case Rep Gastroenterol 2013; 7:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2014; 113:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996; 2:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuta GT, Sherman P. Eotaxin and eosinophilic homing to the gut. J Pediatr Gastroenterol Nutr 2000; 30:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006; 116:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard C, Stucke EM, Rodriguez-Jimenez B, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol 2011; 127:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishra A, Hogan SP, Brandt EB, Rothenberg ME. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest 2001; 107:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucendo AJ, De Rezende L, Comas C, et al. Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis. Am J Gastroenterol 2008; 103:2184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishra A, Wang M, Pemmaraju VR, et al. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology 2008; 134:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology 2009; 137:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol 2010; 184:4033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuo L, Fulkerson PC, Finkelman FD, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. J Immunol 2010; 185:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu X, Wang M, Mavi P, et al. Interleukin-15 expression is increased in human eosinophilic esophagitis and mediates pathogenesis in mice. Gastroenterology 2010; 139:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuta GT, Straumann A. Review article: the pathogenesis and management of eosinophilic oesophagitis. Aliment Pharmacol Ther 2006; 24:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta SK, Fitzgerald JF, Kondratyuk T, HogenEsch H. Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2006; 42:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishra A, Hogan SP, Brandt EB, Rothenberg ME. IL-5 promotes eosinophil trafficking to the esophagus. J Immunol 2002; 168:2464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard C, Mingler MK, Vicario M, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol 2007; 120:1292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kottyan LC, Davis BP, Sherrill JD, et al. Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet 2014; 46:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis BP, Stucke EM, Khorki ME, et al. Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment. JCI Insight 2016; 1:e86355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishra A, Weaver TE, Beck DC, Rothenberg ME. Interleukin-5-mediated allergic airway inflammation inhibits the human surfactant protein C promoter in transgenic mice. J Biol Chem 2001; 276:8453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 2003; 125:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2015; 135:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology 2020; 158:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothenberg ME, Spergel JM, Sherrill JD, et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet 2010; 42:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abonia JP, Wen T, Stucke EM, et al. High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol 2013; 132:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherrill JD, Gao PS, Stucke EM, et al. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol 2010; 126:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azouz NP, Ynga-Durand MA, Caldwell JM, et al. The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses. Sci Transl Med 2018; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulder DJ, Pacheco I, Hurlbut DJ, et al. FGF9-induced proliferative response to eosinophilic inflammation in oesophagitis. Gut 2009; 58:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucendo AJ, Arias A, De Rezende LC, et al. Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: a prospective study. J Allergy Clin Immunol 2011; 128:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaymak T, Kaya B, Wuggenig P, et al. IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis. Gut 2023; 72:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abonia JP, Blanchard C, Butz BB, et al. Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 2010; 126:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niranjan R, Mavi P, Rayapudi M, et al. Pathogenic role of mast cells in experimental eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol 2013; 304:G1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aceves SS, Newbury RO, Dohil R, et al. Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2007; 119:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman JA, Zhang J, Whitworth J, Cavender C. A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis. Ann Allergy Asthma Immunol 2018; 120:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu TX, Sherrill JD, Wen T, et al. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol 2012; 129:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004; 351:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander ES, Martin LJ, Collins MH, et al. Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis. J Allergy Clin Immunol 2014; 134:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen ET, Kuhl JT, Martin LJ, et al. Early-life environmental exposures interact with genetic susceptibility variants in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol 2018; 141:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brusilovsky M, Bao R, Rochman M, et al. Host-Microbiota Interactions in the Esophagus During Homeostasis and Allergic Inflammation. Gastroenterology 2022; 162:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kottyan LC, Rothenberg ME. Genetics of eosinophilic esophagitis. Mucosal Immunol 2017; 10:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller DE, Forney C, Rochman M, et al. Genetic, Inflammatory, and Epithelial Cell Differentiation Factors Control Expression of Human Calpain-14. G3 (Bethesda) 2019; 9:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyles JL, Martin LJ, Shoda T, et al. Very early onset eosinophilic esophagitis is common, responds to standard therapy, and demonstrates enrichment for CAPN14 genetic variants. J Allergy Clin Immunol 2021; 147:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins MH, Blanchard C, Abonia JP, et al. Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol 2008; 6:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guajardo JR, Plotnick LM, Fende JM, et al. Eosinophil-associated gastrointestinal disorders: a world-wide-web based registry. J Pediatr 2002; 141:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherrill JD, Kc K, Wang X, et al. Whole-exome sequencing uncovers oxidoreductases DHTKD1 and OGDHL as linkers between mitochondrial dysfunction and eosinophilic esophagitis. JCI Insight 2018; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kottyan LC, Parameswaran S, Weirauch MT, et al. The genetic etiology of eosinophilic esophagitis. J Allergy Clin Immunol 2020; 145:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherrill JD, Kiran KC, Blanchard C, et al. Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA sequencing. Genes Immun 2014; 15:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin LJ, He H, Collins MH, et al. Eosinophilic esophagitis (EoE) genetic susceptibility is mediated by synergistic interactions between EoE-specific and general atopic disease loci. J Allergy Clin Immunol 2018; 141:1690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kottyan LC, Trimarchi MP, Lu X, et al. Replication and meta-analyses nominate numerous eosinophilic esophagitis risk genes. J Allergy Clin Immunol 2021; 147:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang X, March M, Mentch F, et al. A genome-wide association meta-analysis identifies new eosinophilic esophagitis loci. J Allergy Clin Immunol 2022; 149:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rochman M, Azouz NP, Rothenberg ME. Epithelial origin of eosinophilic esophagitis. J Allergy Clin Immunol 2018; 142:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen T, Stucke EM, Grotjan TM, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology 2013; 145:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keely S, Talley NJ. Endophenotyping eosinophilic oesophagitis: a new era for management? Lancet Gastroenterol Hepatol 2018; 3:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn JLM, Shoda T, Caldwell JM, et al. Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort. J Allergy Clin Immunol 2020; 145:1629.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 90146 Version 9.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21477849" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Eosinophilic esophagitis: updated consensus recommendations for children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12145607" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Eosinophilic esophagitis: it's not just kid's stuff.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14713902" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Eosinophilic gastrointestinal disorders (EGID).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26685124" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30009819" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10841566" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A critical role for eotaxin in experimental oral antigen-induced eosinophilic gastrointestinal allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10377178" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Fundamental signals that regulate eosinophil homing to the gastrointestinal tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28131390" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Calpain-14 and its association with eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30958799" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24220297" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34815391" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Desmoplakin and periplakin genetically and functionally contribute to eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10359874" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Food allergy. Part 2: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10329801" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Food allergy. Part 1: immunopathogenesis and clinical disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15825090" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Gastrointestinal food allergy: new insights into pathophysiology and clinical perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11742273" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3898714" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Eosinophilic gastroenteritis. Immunohistochemical evidence for IgE mast cell-mediated allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24439077" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Electron microscopy elucidates eosinophil degranulation patterns in patients with eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24813515" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Genetic and epigenetic underpinnings of eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35175645" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mast cell-pain connection in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27130859" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Food-specific IgG4 is associated with eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24907494" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26466342" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Oesophageal intrasquamous IgG4 deposits: an adjunctive marker to distinguish eosinophilic oesophagitis from reflux oesophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11842310" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10199468" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Allergic esophagitis in children: a clinicopathological entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/456850" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Eosinophilic gastroenteritis in extreme allergy. Immunopathological comparison with nonallergic gastrointestinal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1138168" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Serum IgE in eosinophilic gastroenteritis. Response to intestinal challenge in two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/517550" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Eosinophilic gastroenteritis--a complex disease entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7096820" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Food allergy manifested by eosinophilia, elevated immunoglobulin E level, and protein-losing enteropathy: the syndrome of allergic gastroenteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The role of the eosinophil in gastrointestinal diseases
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8613639" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Gastroesophageal reflux and cow's milk allergy in infants: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9396650" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Food allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21593640" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Role of eosinophils in inflammatory bowel and gastrointestinal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7557132" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22541246" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16143136" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19577011" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17450024" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Is there a seasonal variation in the incidence or intensity of allergic eosinophilic esophagitis in newly diagnosed children?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19240704" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Seasonal distribution in newly diagnosed cases of eosinophilic esophagitis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16297137" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Eosinophil infiltration of the oesophageal mucosa in patients with pollen allergy during the season.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24636095" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Esophageal hypereosinophilia induced by grass sublingual immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24163646" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Induction of eosinophilic esophagitis by sublingual pollen immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25216976" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8597956" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749400" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Eotaxin and eosinophilic homing to the gut.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16453027" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21211656" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A striking local esophageal cytokine expression profile in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134183" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : An etiological role for aeroallergens and eosinophils in experimental esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18844613" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18166354" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19596009" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Biology and treatment of eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20208004" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20543112" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20381491" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Interleukin-15 expression is increased in human eosinophilic esophagitis and mediates pathogenesis in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16842447" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Review article: the pathogenesis and management of eosinophilic oesophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16385249" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11859139" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : IL-5 promotes eosinophil trafficking to the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18073124" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25017104" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27158675" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11113143" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Interleukin-5-mediated allergic airway inflammation inhibits the human surfactant protein C promoter in transgenic mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14598258" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25226850" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31593702" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20208534" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Common variants at 5q22 associate with pediatric eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23608731" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20620568" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29875205" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18978176" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : FGF9-induced proliferative response to eosinophilic inflammation in oesophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21880354" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35613844" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20538331" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Involvement of mast cells in eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23599040" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Pathogenic role of mast cells in experimental eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17208603" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Esophageal remodeling in pediatric eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29544738" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22391115" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15329438" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25258143" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29029802" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Early-life environmental exposures interact with genetic susceptibility variants in pediatric patients with eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34627858" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Host-Microbiota Interactions in the Esophagus During Homeostasis and Allergic Inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28224995" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Genetics of eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30626591" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Genetic, Inflammatory, and Epithelial Cell Differentiation Factors Control Expression of Human Calpain-14.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33446329" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Very early onset eosinophilic esophagitis is common, responds to standard therapy, and demonstrates enrichment for CAPN14 genetic variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18434257" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12378201" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Eosinophil-associated gastrointestinal disorders: a world-wide-web based registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29669943" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Whole-exome sequencing uncovers oxidoreductases DHTKD1 and OGDHL as linkers between mitochondrial dysfunction and eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31910986" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The genetic etiology of eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24920534" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29129581" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Eosinophilic esophagitis (EoE) genetic susceptibility is mediated by synergistic interactions between EoE-specific and general atopic disease loci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33446330" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Replication and meta-analyses nominate numerous eosinophilic esophagitis risk genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34506852" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A genome-wide association meta-analysis identifies new eosinophilic esophagitis loci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29980278" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Epithelial origin of eosinophilic esophagitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23978633" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Molecular diagnosis of eosinophilic esophagitis by gene expression profiling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29730082" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Endophenotyping eosinophilic oesophagitis: a new era for management?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32197970" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
